Cellectis announced that the FDA has granted Orphan Drug Designation, or ODD, to Cellectis’ CLLS52, an Investigational Medicinal Product used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Cellectis Gains FDA Orphan Drug Status for ALL Therapy
- FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
- CLLS Earnings this Week: How Will it Perform?
- Cellectis Gains FDA Designations for Leukemia Therapy
- FDA grants Cellectis’ UCART22 ODD and RPDD status for ALL treatment